Xenex Expands Board of Directors with Addition of Accounting Industry Leader Aaron deSouza

SAN ANTONIO--(BUSINESS WIRE)--Xenex Disinfection Services, a world leader in UV disinfection technology for healthcare facilities, today announced Aaron deSouza has joined its board of directors. He is working closely with Xenex’s leadership team and other board members to support Xenex’s strategic growth initiatives.

DeSouza has significant experience supporting boards of directors and audit committees with strategy, finance, risk mitigation, internal controls, regulatory filings and IPO (initial public offering) matters. Prior to starting his own firm, he was a partner and U.S. Audit Leader for Private Equity at Grant Thornton LLP (Atlanta). He also worked for Deloitte LLP where he advised on audit, accounting, and U.S. and international mergers and acquisitions. He is a graduate of the University of Pune (India) and received his Masters of Public Accountancy degree from the University of Southern Mississippi.

“Xenex is a mission-driven and evidence-based company, and I’m honored to serve on their board of directors and support the Xenex team as they expand their LightStrike disinfection technology throughout hospital systems and around the world,” said deSouza.

As a result of the COVID-19 pandemic, the world is focused on preventing the spread of viruses and bacteria, which has led to significant growth for Xenex. Researchers have published 45 peer-reviewed studies validating Xenex’s LightStrike patented pulsed xenon ultraviolet (UV) room disinfection technology, including the robot’s efficacy in quickly destroying SARS-CoV-2 (the virus that causes COVID-19). Thousands of LightStrike Germ-Zapping Robots are deployed around the world in hospitals, outpatient surgery centers, hospices, schools, government buildings, airports, hotels, sports arenas, jails and correctional facilities, and more.

DeSouza joins a highly experienced group of industry veterans serving on Xenex’s board of directors, including Brooks Andrews, Managing Director at EW Healthcare Partners; Cathy Burzik, CEO of CFB Interests, LLC and former president and CEO of Kinetic Concepts, Inc.; Sean Murphy, co-founder of Malin Life Sciences Holding, PLC and former Abbott Laboratories and Evercore executive; Matt Rhodes-Kropf, managing partner of Tectonic Ventures and a professor at MIT; and Morris Miller, CEO of Xenex.

About Xenex

Xenex is a world leader in UV technology-based disinfection strategies and solutions. Frost & Sullivan named Xenex the 2020 Global Company of the Year for its patented technology and being at the vanguard of the fight against SARS-CoV-2. Xenex is focused on developing, manufacturing and commercializing products and services that utilize its innovative, proprietary disinfection technologies to stop the spread of deadly pathogens that cause infectious diseases. Xenex is backed by well-known investors that include EW Healthcare Partners, Piper Sandler, Malin Corporation, Battery Ventures, Targeted Technology Fund II, Tectonic Ventures and RK Ventures. For more information, visit xenex.com.